Print（PDF/130KB） Oct. 31, 2023 Finances

Notice Concerning Finance Income

Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura; Securities Code: 4506, Prime Market of TSE) announced today that it recorded finance income for the second quarter of the fiscal year ending March 31, 2024 (from April 1, 2023 to September 30, 2023) as follows.

1. Details of Finance Income

The Company recorded a foreign exchange gain of 30,133 million yen under finance income for the second quarter of the fiscal year ending March 31, 2024 due to recent fluctuations in foreign exchange rates. This was mainly due to the valuation of assets denominated in foreign currencies.

2. Future Outlook

Regarding the impact of the above finance income on the results of the Company operations, please refer to the “Summary of Consolidated Financial Results for the Second Quarter of the Year Ending March 31, 2024 [IFRS]” announced today. Since the amount will fluctuate depending on the future foreign exchange rates, the Company has not revised the financial forecasts at this time.